BrainStorm Expands Patent Coverage of NurOwn Therapy for ALS, Parkinson’s
November 5, 2017 - als
BrainStorm Cell Therapeutics is expanding a obvious portfolio that protects a NurOwn record for a diagnosis of several diseases inspiring a executive shaken system. The latest U.S. obvious explain includes Parkinson’s illness and ALS (amyotrophic parallel sclerosis).
The proclamation by BrainStorm follows a Notice of Allowance released by a U.S. Patent and Trademark Office (USPTO) for a obvious focus (No. 14/173,846) patrician “Isolated Cells and Populations Comprising Same for a Treatment of CNS Diseases.”
A Notice of Allowance indicates a invention qualifies for a patent. But additional fees and obvious processes are compulsory before a obvious is entirely protected. Until then, a obvious is still deliberate as pending.
“We continue to strengthen a record by vital egghead skill [IP] achievements and this Notice of Allowance from a USPTO is a acquire further to a IP portfolio,” Chaim Lebovits, CEO of BrainStorm, pronounced in a press release.
The expansion of NurOwn started in a laboratory of Prof. Dani Offen during Tel Aviv University. Offen is now a arch systematic confidant during BrainStorm. NurOwn is a dungeon therapy that uses mesenchymal branch cells (MSCs) as a healing core for a diagnosis of neurodegenerative disorders.
MSCs are predecessor cells found via a body, generally in fat hankie and bone marrow.
These cells furnish signaling molecules that umpire a activity of other cells in their vicinity, that led researchers to examine them as regulators of defence and inflammatory responses.
But additional studies suggested their activity was broader. One sold underline of these cells was their ability to hide neurotrophic factors (NTF), that are concerned in a growth, survival, and split of haughtiness cells (neurons). This upheld a supposition that MSCs could be intensity modulators of neurodegeneration, while safeguarding neurons from damage.
Preclinical studies with rodent models of several neurodegenerative diseases, including ALS, sciatic haughtiness injury, Parkinson’s disease, and mixed sclerosis, reliable a efficiency of MSCs on safeguarding neurons from toxin-induced damage.
In addition, formula from a Phase 2 clinical trial (NCT02017912) showed that diagnosis with NurOwn branch dungeon therapy was protected and could satisfy clinically suggestive improvements in ALS patients. The diagnosis softened a patients’ organic capacity, flesh strength, and respiratory capacity, with a auspicious response rate.
Currently, BrainStorm is exploring NurOwn as an ALS diagnosis in a Phase 3 trial (NCT03280056). The study, that is now recruiting participants, is being conducted at six ALS clinical centers in a U.S. For information, go to this site and corkscrew down to Contacts and Locations.
Print This Page